JTO Clinical and Research Reports (Mar 2022)

Unusual Resistance Mechanisms in a Case of ROS1-Rearranged NSCLC: A Case Report

  • Ullas Batra, MD,
  • Shrinidhi Nathany, MD,
  • Mansi Sharma, MD,
  • Sakshi Mattoo, MSc,
  • Joslia T. Jose, MTech,
  • Anurag Mehta, MD

Journal volume & issue
Vol. 3, no. 3
p. 100286

Abstract

Read online

The unprecedented growth of the high-throughput next-generation sequencing has facilitated the identification of rare oncogene fusions such as ROS1 for NSCLC. ROS1 rearrangement has been observed in only 2% of cases of NSCLC and has been successfully targeted using various tyrosine kinase inhibitors including crizotinib. However, the on-target and off-target mechanisms of the resistance are still vague. Here, we report a case of a patient with ROS1 rearranged NSCLC presenting primary resistance to crizotinib.

Keywords